Form 8K Opus Genetics Inc For: 11 September
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Opus Genetics Inc (IRD)
Opus Genetics Inc stock price live, this page displays NASDAQ IRD stock exchange data. View the IRD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Opus Genetics Inc real time stock price chart below.
What Is the Opus Genetics Inc Stock Price Today?
The Opus Genetics Inc stock price today is 4.830.
What Is the Stock Symbol for Opus Genetics Inc?
The stock symbol for Opus Genetics Inc is "IRD."
What Stock Exchange Does Opus Genetics Inc Trade On?
Opus Genetics Inc is listed and trades on the NASDAQ stock exchange.
Is Opus Genetics Inc a Good Stock to Buy?
Determining whether Opus Genetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IRD quote. (ISIN: US67577R1023)
What Is the Opus Genetics Inc Stock Price Today?
The Opus Genetics Inc stock price today is 4.830.
What Is the Stock Symbol for Opus Genetics Inc?
The stock symbol for Opus Genetics Inc is "IRD."
What Stock Exchange Does Opus Genetics Inc Trade On?
Opus Genetics Inc is listed and trades on the NASDAQ stock exchange.
Is Opus Genetics Inc a Good Stock to Buy?
Determining whether Opus Genetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IRD quote. (ISIN: US67577R1023)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.645
5.155
52 wk Range
1.500
7.070
IRD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.6455.155
52 wk Range
1.5007.070
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IRD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
13.000
Upside
+169.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
18 Buy
0 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.000
(+169.15% Upside)
Earnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.14 / -0.16
Revenue / Forecast
755K / 2.63M
Compare IRD to Peers and Sector
Metrics to compare | IRD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIRDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.7x | −1.5x | −0.4x | |
PEG Ratio | −0.26 | −0.05 | 0.00 | |
Price/Book | −30.9x | 2.5x | 2.6x | |
Price / LTM Sales | 40.8x | 102.4x | 3.1x | |
Upside (Analyst Target) | 159.0% | 301.8% | 55.6% | |
Fair Value Upside | Unlock | 18.6% | 7.8% | Unlock |
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Opus Genetics (IRD) Stock Price Today?
The Opus Genetics stock price today is 4.830 USD.
What Stock Exchange Does Opus Genetics Trade On?
Opus Genetics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Opus Genetics?
The stock symbol for Opus Genetics is "IRD."
What Is the Opus Genetics Market Cap?
As of today, Opus Genetics market cap is 401.840M USD.
What Is Opus Genetics's Earnings Per Share (TTM)?
The Opus Genetics EPS (TTM) is -1.293.
When Is the Next Opus Genetics Earnings Date?
Opus Genetics will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is IRD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Opus Genetics Stock Split?
Opus Genetics has split 3 times.
How Many Employees Does Opus Genetics Have?
Opus Genetics has 28 employees.
What is the current trading status of Opus Genetics (IRD)?
As of Sep 24, 2026, Opus Genetics (IRD) is trading at a price of 4.830 USD, with a previous close of 4.830 USD. The stock has fluctuated within a day range of 4.645 USD to 5.155 USD, while its 52-week range spans from 1.500 USD to 7.070 USD.
What Is Opus Genetics (IRD) Price Target According to Analysts?
The average 12-month price target for Opus Genetics is 13.000 USD, with a high estimate of 20 USD and a low estimate of 8 USD. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +169.15% Upside potential.
What Is the IRD Premarket Price?
IRD's last pre-market stock price is 4.790 USD. The pre-market share volume is 1,060.000, and the stock has decreased by -0.040, or -0.830%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.